Houston pharma co. to sell facility to MD Anderson Cancer Center

Houston-based Bellicum Pharmaceuticals Inc. (Nasdaq: BLCM), a clinical-stage biopharmaceutical company focused on cellular immunotherapies, is selling a local facility to the University of Texas M.D. Anderson Cancer Center.

M.D. Anderson will pay $15 million for the 60,000-square-foot facility at 2130 W. Holcombe Blvd., which includes manufacturing, office and laboratory space, according to a Jan. 21 press release and filing with the U.S. Securities and Exchange Commission. Approximately 35 employees…